

# Yasushi Honda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3173184/publications.pdf>

Version: 2024-02-01

30  
papers

1,206  
citations

623188

14  
h-index

500791

28  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1611  
citing authors

#	ARTICLE	IF	CITATIONS
1	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. <i>Gastroenterology</i> , 2016, 150, 626-637.e7.	0.6	628
2	Nonalcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1009-1014.	1.4	69
3	Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 908-917.e11.	2.4	57
4	Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001990.	1.2	53
5	Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. <i>Journal of Gastroenterology</i> , 2021, 56, 1022-1032.	2.3	49
6	Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4039.	1.8	35
7	<i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1795-1803.	1.4	34
8	Magnetic resonance elastography increases usefulness and safety of noninvasive screening for esophageal varices. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 2022-2028.	1.4	30
9	Gut microbiota composition associated with hepatic fibrosis in nonobese patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2275-2284.	1.4	26
10	Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 1136-1146.	1.8	24
11	Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. <i>World Journal of Gastroenterology</i> , 2021, 27, 609-623.	1.4	24
12	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 996-1007.	3.7	22
13	Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 872-880.	1.8	19
14	Advances in ultrasound elastography for nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 521-533.	0.6	17
15	Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. <i>Hepatology Communications</i> , 2022, 6, 2273-2285.	2.0	17
16	Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs. <i>Diagnostics</i> , 2020, 10, 912.	1.3	15
17	Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2021, 68, 181-186.	0.6	13
18	Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with nonalcoholic fatty liver disease: A multicenter study. <i>Hepatology Research</i> , 2020, 50, 955-965.	1.8	12

#	ARTICLE	IF	CITATIONS
19	Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100516.	0.5	11
20	Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 535-548.	0.6	9
21	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 186-195.	3.6	9
22	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4939.	1.8	8
23	Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis index than low cut-off index. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1411-1416.	1.4	6
24	Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. <i>BMJ Open</i> , 2020, 10, e037961.	0.8	6
25	Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. <i>Contemporary Clinical Trials</i> , 2018, 69, 40-47.	0.8	4
26	What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1217-1220.	0.9	4
27	Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake. <i>Oncologist</i> , 2021, 26, e1862-e1869.	1.9	2
28	Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study. <i>BMJ Open</i> , 2022, 12, e060335.	0.8	2
29	Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype. <i>Frontiers in Oncology</i> , 2020, 10, 555963.	1.3	1
30	A case of hepatitis B virus reactivation with hemochromatosis after allogeneic bone marrow transplantation for acute myeloid leukemia. <i>Acta Hepatologica Japonica</i> , 2020, 61, 504-512.	0.0	0